Dishang Bhavsar, MD
Interventional Cardiology · Bolivar, MONPI 1528588670
Payments from drug & device makers
What this record shows
Boston Scientific accounts for 68.8% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,912, more than ten times the $20 reported in 2022. That places this record below the midpoint for interventional cardiology clinicians in MO, where the typical reported total is $10,448.
Across 46 payments — averaging $76.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Philips North America LLC$647
- Shockwave Medical, Inc$230
- Medtronic$84
- Amgen$62
- Irhythm Technologies, Inc.$58
- plus $15 from 1 others
What the payments were for
- Travel & lodging$1,53244%
- Food & beverage$1,97456%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 25 | $2,410 |
| Philips North America LLC | 11 | $647 |
| Shockwave Medical, Inc | 3 | $230 |
| Medtronic | 2 | $84 |
| Amgen | 3 | $62 |
| Irhythm Technologies, Inc. | 1 | $58 |
| Chiesi USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,505 in reported general payments places this provider in the 25th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $22,503 |
| Metoprolol Succinate | 76 | $500 |
| Ezetimibe | 13 | $355 |
| Atorvastatin Calcium | 52 | $307 |
| Rosuvastatin Calcium | 29 | $184 |
| Lisinopril | 25 | $100 |
| Losartan Potassium | 21 | $71 |
| Spironolactone | 18 | $62 |
| ClopidogrelClopidogrel Bisulfate | 11 | $55 |
| Furosemide | 16 | $37 |
| Amlodipine Besylate | 31 | $35 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Bolivar
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.